Explore the Agenda
Introduction to ADCs Day
5th Novel Conjugates Day
4th Toxicity Day
5th ADCs in Combination Day
3rd Regulatory CMC Day
Introduction to ADCs Day
Introduction to ADCs Day
Consultant & Honorary Professor, Queen's University Belfast
President & Founder, Bramhill Biological Consulting
New to ADCs? Join our ADC 101 Workshop and build a strong foundation before the main conference. Designed for those entering the field, this expert-led session from long-standing ADC KOLs covering the key scientific breakthroughs, clinical lessons, and innovations that have shaped today’s ADC landscape.
8:15 am Check In, Morning Coffee & Light Refreshments
9:15 am The morning session will cover:
- Understanding the foundational lessons that shaped modern ADC design and helped overcome early development challenges
- Evaluating key ADC components, including payload selection and linker chemistry, to optimise efficacy and safety
- Assessing the impact of conjugation site selection on ADC performance, stability, and therapeutic outcomes
12:30 pm Lunch Break & Networking
1:30 pm The afternoon session will cover:
- Understanding the biological principles of ADCs and selecting the most appropriate target and antibody format
- Analysing the key choices, trade-offs, and design considerations across the ADC chemistry toolbox
- Evaluating preclinical in vivo efficacy data and the critical factors that inform successful ADC development and translation to the clinic
2:30 pm End of Introduction to ADCs Day
5th Novel Conjugates Day
4th Toxicity Day
5th ADCs in Combination Day
3rd Regulatory CMC Day
11:00 am Morning Break & Antibody Drug Connection Building
5th Novel Conjugates Day
Designing Better ADCs: From Smarter Payloads, Smarter Conjugation & Computational Tools
11:30 am Progressing a Phase I Trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)- Enabled Peptide-Drug Conjugate Delivering Sustained Tumour Microenvironment Release of Exatecan in Patients with FAP-Positive Solid Tumours
Associate Director Clinical Science & Translational Medicine, Avacta Therapeutics
- Leveraging peptide-drug conjugate designs to selectively release potent cytotoxic payloads within the tumour microenvironment through FAPmediated linker cleavage to maximise tumour exposure while minimising systemic toxicity
- Advancing AVA6103 (FAP-activated exatecan; FAPExd), through Phase 1a dose escalation, with Phase 1b expansion anticipated to commence in 2027
- Highlighting emerging data into target engagement, mechanism of action and the potential of FAPenabled tumour-selective drug delivery in several solid-tumour types
12:00 pm Beyond ADCs: FAP-Targeted Small-Molecule Conjugates for Tumour-Selective Delivery of Immunostimulatory Payloads
Research Scientist, Philochem
- Introducing small-molecule drug conjugates (SMDCs) as an innovative approach for targeted cancer therapy, highlighting their design principles and potential advantages for selective payload delivery
- Exploring novel payloads beyond conventional cytotoxic agents, with a particular focus on small-molecule conjugates designed to promote localized immune activation within the tumour microenvironment
- Sharing preclinical findings demonstrating the anti tumour potential of FAP-targeted small-molecule conjugates, including their ability to induce potent and durable anti-tumour responses
4th Toxicity Day
5th ADCs in Combination Day
3rd Regulatory CMC Day
12:30 pm Lunch & Networking
5th Novel Conjugates Day
Tackling Tumour Heterogeneity with Next-Generation Payloads & Multi-Specific ADCs
1:30 pm Creating Multi-specific ADCs to Overcome Tumour Heterogeneity & Improve Specificity
Chief Executive Officer & Founder, Oxford BioTherapeutics Ltd
- Delivering broader tumour targeting and more robust anti-tumour activity with multi-specific ADCs by simultaneously engaging multiple antigens
- Addressing tumour heterogeneity with multi TAA targeting may enhance response rates and durability only when optimal antigen pairings are selected
- Reducing the risk of on-target toxicity and antigen escape that arises from single-antigen loss, provided that antigen pairings minimise rather than exacerbate normal tissue liabilities
2:00 pm Advancing a Novel Payload AxcynDOT & Its Application in First-in-Class Anti-CLDN6-ADC
Founder & Chief Executive Officer, Axcynsis Therapeutics
- Outlining the AxcynDOT payload technology to overcome drug resistance
- Design and developing AT-03, a first-in-class anti CLDN6 ADC
- Presenting key pre-clinical and clinical development insights from AT03
4th Toxicity Day
5th ADCs in Combination Day
3rd Regulatory CMC Day
Afternoon Break & Networking
ADC Licensing, Partnering & Investments
Exclusively designed for search and evaluation, external evaluation, business development leads, C-level biotech leaders, and venture capital investors, the ADC Licensing, Partnering & Investment afternoon session is the place to be to understand diverse perspectives on what ADC innovation is showing most promise, how best to balance novelty versus risk to investors, and biopharma decision-maker attitudes when evaluating ADC deal-making opportunities in 2027.
Open to all registered attendees.
3:20 pm Chair’s Opening Remarks
3:30 pm Antibody–Drug Conjugates: Promise & Challenges for Innovation & Investment
- Antibody–drug conjugates are one of oncology’s most promising modalities — delivering potent, targeted therapy more selectively than conventional chemotherapy across the patient journey
- But success is scientifically demanding, depending not on the target alone but on the disciplined integration of biology, engineering and patient selection
- Outlining the critical success factors underpinning ADC development, highlighting how a holistic, end-to-end strategy can maximise clinical efficacy, improve safety, and unlock the full therapeutic potential of next-generation ADCs and making it an attractive investment opportunity
3:50 pm Can a New Partnership Ecosystem Help Solve for the Emerging Bottlenecks in ADC Development?
- ADC development has become increasingly challenging and meaningful differentiation exceedingly difficult due to an explosion in competition
- More than ever, time- and cost-efficient development execution is essential to be able to win in this crowded landscape
- Designing a new model of a Global Development SuperHighway to create win-win partnership opportunities and solve the problem of access to high-quality and efficient development execution
4:10 pm Panel Discussion: Financing the Next Generation of Safer, More Effective ADCs Through Biopharma Partnerships, Collaborations & Investment Strategies
Discover what drives licensing decisions, investment strategies, and M&A activity, from making your ADC programmes attractive to where the next shift in the industry is heading. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.
- Discussion 1 – Building the Next Wave of ADC Drugs Through Biopharma Acquisitions & Technology Scouting
- Discussion 2 – Turbocharging Biotech Innovation & Differentiation to Achieve Successful Fund Raising Rounds